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 While smoking rates in the general adult population have declined, smoking 
remains entrenched among individuals with opioid use disorder (OUD).  Individuals with 
OUD have an extremely high prevalence of smoking, experience poor cessation outcomes, 
and bear a disproportionate burden of smoking-related adverse health consequences.  Data 
have also suggested that opioid-maintained (OM) smokers may experience a unique 
response to nicotine including heightened reinforcement and potentially more severe 
withdrawal when stopping smoking.  Thus, this is a sub-group of smokers for which novel 
harm reduction paradigms are urgently needed to reduce the burden of smoking.  A 
promising national policy is currently under consideration by the Food and Drug 
Administration to decrease the nicotine content of cigarettes in an effort to reduce smoking 
prevalence and smoking-related disease.  It is critical to understand the extent to which 
reduced nicotine content cigarettes (RNCCs) can attenuate tobacco withdrawal severity in 
OM smokers as this has direct implications for the potential acceptability and uptake of 
reduced nicotine cigarettes in this vulnerable subgroup.  
 
 The primary aims of this study were to rigorously examine the effects of OM 
status on tobacco withdrawal and craving in response to participants’ usual brand cigarette 
and research cigarettes that varied in nicotine content.  Opioid-maintained (OM; n=65) vs. 
non opioid-maintained (NOM; n=135) smokers completed 5 outpatient laboratory sessions 
in which they smoked a single research cigarette varying in nicotine content (0.4, 2.4, 5.2, 
15.8 mg/g of tobacco) or their usual brand cigarette under double-blind, acute abstinence 
conditions.  Participants completed the Minnesota Tobacco Withdrawal Scale before and 
every 15 minutes for one hour following smoking each cigarette.  As an exploratory aim, 
we also examined the contribution of OM status to tobacco withdrawal in the context of 
several other important characteristics associated with smoking vulnerability (e.g., 
depression, anxiety, education level).  Repeated measures mixed model analyses were used 
to examine all aims. 
 
  Across usual brand cigarettes and RNCCs, tobacco withdrawal and craving did 
not differ as a function of OM status (p’s >.05).  In multivariable models, nicotine dose, 
time, depression, cigarette dependence, education level, but not OM status, consistently 
predicted tobacco withdrawal and craving severity (p’s <.05).  In particular, depression 
severity, rather than OM status, was the strongest and most consistent predictor of 
withdrawal and craving severity among the characteristics examined. 
 
 Despite prior data suggesting that OM smokers may respond differently to 
nicotine and experience more severe withdrawal during reductions in nicotine intake, OM 
smokers in this study responded favorably to RNCCs.  These findings provide additional 
support for the potential beneficial effects of a national nicotine reduction policy for 
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CHAPTER 1: INTRODUCTION 
1.1. Cigarette Smoking Among Individuals with Opioid Use Disorder 
Despite considerable progress in tobacco control and prevention, cigarette 
smoking remains the leading cause of preventable death and disability in the United 
States (US) and is responsible for nearly 500,000 deaths each year (US Department of 
Health and Human Services, 2014).  While the prevalence of smoking among the general 
US adult population has declined over the past several decades, it remains entrenched 
among certain vulnerable populations.  This is especially the case among individuals with 
co-morbid substance use disorders (SUDs), non-SUD psychiatric disorders and 
socioeconomic disadvantage, all of whom are overrepresented among current cigarette 
smokers and bear a disproportionate burden of smoking-related disease (Hiscock, Bauld, 
Amos, Fidler, & Munafò, 2012; Schroeder & Morris, 2010).  For example, while 
smoking prevalence has markedly decreased among individuals without SUDs, recent 
nationally-representative data suggests that the prevalence of cigarette smoking in the 
US is actually increasing among those with SUDs, excluding cannabis use disorders 
(Weinberger et al., 2018). 
Individuals with opioid use disorder (OUD) represent a population that is 
particularly vulnerable to cigarette smoking and its adverse health effects.  Prevalence of 
smoking in this group is up to six-fold higher than the general population (84-94% vs. 
15%, respectively)(Guydish et al., 2011, 2016; Hser, Hoffman, Grella, & Anglin, 2001; 
Hser et al., 1994; Jamal, 2016; Nahvi, Richter, Li, Modali, & Arnsten, 2006; Richter, 
Gibson, Ahluwalia, & Schmelzle, 2001), and the incidence of all-cause mortality is four-
fold that of nonsmokers with OUD (Hser et al., 1994).  Prevalence of smoking is also 
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higher among individuals in treatment for OUD compared to other SUDs (Guydish et al., 
2016, 2011).  Finally, individuals with OUD often present with additional risk factors 
that may further increase their risk for smoking and related adverse consequences, 
including increased prevalence of comorbid non-SUD psychiatric disorders (e.g., 
depression and personality disorders) and socioeconomic disadvantage (e.g., limited 
educational attainment), both of which are independently associated with increased 
prevalence rates of smoking and poorer cessation outcomes (e.g., Higgins & Chilcoat, 
2009; Hiscock et al., 2012; Kurti et al., 2016; Lasser et al., 2000).  
Most individuals with OUD are aware of the health risks of smoking, express an 
interest in quitting, and express interest in receiving smoking cessation services (Clarke, 
Stein, McGarry, & Gogineni, 2001; Clemmey, Brooner, Chutuape, Kidorf, & Stitzer, 
1997; Dunn, Sigmon, Reimann, Heil, & Higgins, 2009; Frosch, Shoptaw, Jarvik, 
Rawson, & Ling, 1998; Kozlowski, Skinner, Kent, & Pope, 1989; Nahvi et al., 2006; 
Richter et al., 2001; Sees & Clark, 1993).  Despite this, responses to smoking cessation 
interventions are notoriously poor in this group, with abstinence outcomes one-fourth 
that of non-substance abusing smokers (Miller & Sigmon, 2015; Okoli et al., 2010; 
Zirakzadeh, Shuman, Stauter, Hays, & Ebbert, 2013) and standard first-line 
pharmacotherapies largely ineffective (Dunn et al., 2010; Miller & Sigmon, 2015; Okoli 
et al., 2010; Zirakzadeh et al., 2013).   
 
1.2. Nicotine Dependence in Smokers with OUD 
While the specific factors contributing to the elevated smoking prevalence and 
poor cessation outcomes among individuals with OUD are not well understood, one 
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possibility is that smokers with concurrent SUDs may present with more severe nicotine 
dependence than smokers without co-occurring SUDs.  Nicotine dependence (referred to 
as tobacco use disorder in the Diagnostic and Statistical Manual of Mental Disorders, 5th 
edition (DSM-5)) is characterized by tolerance, withdrawal and craving for nicotine 
during abstinence, and loss of control over the amount or duration of use (American 
Psychiatric Association, 2013).   
Rates of nicotine dependence are two to four times higher in adults with current 
SUDs compared to the general population (Grant, Hasin, Chou, Stinson, & Dawson, 
2004).  However, there is little research investigating nicotine dependence severity 
among individuals with OUD specifically.  We recently examined associations between 
OUD and nicotine dependence using nationally representative cross-sectional data from 
the National Survey on Drug Use and Health (Parker, Streck, & Sigmon, 2018).  After 
adjusting for baseline characteristics, adult daily smokers with OUD were roughly twice 
as likely to be dependent on nicotine as compared to those without OUD.  Smokers with 
OUD also evidenced a greater severity of nicotine dependence compared to those without 
OUD as measured by the Nicotine Dependence Severity Scale (NDSS; Shiffman, Waters, 
& Hickcox, 2004).  Importantly, greater baseline severity of nicotine dependence has 
been shown to predict poorer cessation outcomes in the general smoker population 
(Borland, Yong, O’Connor, Hyland, & Thompson, 2010; Breslau, Johnson, Hiripi, & 
Kessler, 2001; Fagerstrom & Schneider, 1989; Kozlowski, Porter, Orleans, Pope, & 
Heatherton, 1994; Transdisciplinary Tobacco Use Research Center et al., 2007; Vangeli, 
Stapleton, Smit, Borland, & West, 2011).  
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1.3. Tobacco Withdrawal in Smokers with OUD 
Tobacco withdrawal, a hallmark feature of nicotine dependence, may also play a 
role in opioid-dependent individuals’ smoking behavior.  Given the high rates of 
smoking, nicotine dependence and poor cessation outcomes in this population, for 
example, one might expect to find elevated withdrawal severity upon discontinuation of 
smoking.  In the general smoker population, individuals who experience greater 
withdrawal upon quitting smoking are at increased risk for relapse (Allen, Bade, 
Hatsukami, & Center, 2008; American Psychiatric Association, 2013; Hughes, 2007a; 
Patten & Martin, 1996; West, Hajek, & Belcher, 1989).   
The extant data do suggest elevated incidence and severity of tobacco withdrawal 
among smokers with concurrent SUDs (Breslau, Kilbey, & Andreski, 1992; Hughes, 
1996; Weinberger, Desai, & McKee, 2010).  However, there is a paucity of empirical 
data on tobacco withdrawal among smokers with OUD, and the limited studies thus far 
have produced mixed results.  To our knowledge, only three published studies have 
evaluated tobacco withdrawal among smokers receiving methadone or buprenorphine 
maintenance for treatment of OUD.  In an early report on this topic, Story and Stark 
(1991) examined the efficacy of a methadone dose increase as a pharmacological adjunct 
to a cognitive-behavioral treatment for smoking cessation.  Methadone-maintained 
participants (n=33) were randomly assigned to either an experimental group which 
received a 20% methadone dose increase for a 28-day experimental period or to a control 
group that received a one milligram dose increase for the same duration.  There were no 
significant differences between experimental groups in cigarette abstinence rates, though 
participants receiving the methadone dose increase did report more tobacco withdrawal 
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symptoms than controls.  However, the findings were limited by a sizeable amount of 
continued smoking in both experimental groups.   
In a more recent study, Elkader and colleagues examined methadone and nicotine 
interactions among methadone-maintained patients (n=40) during trough and peak 
methadone dose conditions using a within-subject design (Elkader, Brands, Selby, & 
Sproule, 2009).  Participants rated their tobacco withdrawal symptoms before and after 
self-administering nicotine (own-brand cigarettes, nicotine gum or placebo gum, 
depending on the study day) following 12 hours of smoking abstinence under two 
methadone dosing conditions: Before they ingested their daily methadone dose (at trough 
methadone blood levels) and 3 hours following methadone administration (peak 
methadone blood levels).  In that study, there was a main effect of methadone dose 
condition on tobacco withdrawal severity, whereby tobacco withdrawal was attenuated 
when methadone was at peak (vs. trough) levels.   
 Finally, we recently examined the timecourse and severity of tobacco withdrawal 
among methadone- or buprenorphine-maintained (n=47) vs. non-SUD smokers (n=25), 
all of whom completed one of several two-week studies involving daily visits for 
biochemical monitoring and delivery of financial incentives contingent on smoking 
abstinence (Streck, Heil, Higgins, Bunn, & Sigmon, 2018).   To prevent ongoing smoking 
from confounding evaluations of withdrawal, we examined withdrawal severity among 
the subset of participants who achieved biochemically-verified smoking abstinence.  
While opioid-maintained smokers presented with significantly higher levels of 
withdrawal at study intake (when smoking as usual) relative to the non-SUD smokers, 
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the two groups had remarkably similar profiles of withdrawal across the two-week period 
of smoking abstinence.   
In summary, while tobacco withdrawal severity is associated with relapse to 
smoking and is an important component of continued addiction to cigarettes in the 
general smoker population (Allen et al., 2008; Patkar, Vergare, Batra, Weinstein, & 
Leone, 2003; West et al., 1989), its potential role among smokers with OUD remains 
unclear.  Of the three studies that have examined withdrawal among opioid-dependent 
smokers, one suggested that opioid agonists may be associated with more severe 
withdrawal, one suggested that opioids may attenuate withdrawal, and one found no 
difference in withdrawal between opioid-dependent and non opioid-dependent smokers.  
The methodological differences across these studies may account for these mixed 
findings, as they employed different scientific designs and analytic approaches (e.g., 
within-subject vs. cross-sectional designs, evaluating withdrawal only among abstinent 
vs. all smokers, evaluating smoking during stable vs. acute changes in opioid dose).  
Further, none of the prior studies utilized double-blind nicotine administration or 
examined multiple nicotine doses, and all generally focused on withdrawal following 
abrupt discontinuation of smoking.  
 
1.4. Reducing the Nicotine Content of Cigarettes 
There is an urgent need to understand the severity of withdrawal experienced by 
vulnerable smokers under conditions of reduced nicotine intake.  A national policy is 
currently under consideration to reduce smoking prevalence and smoking-related disease 
in the US by decreasing the nicotine content of cigarettes below the threshold necessary 
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to establish and sustain nicotine dependence (Benowitz & Henningfield, 1994; Gottlieb 
& Zeller, 2017).  The 2009 Family Smoking Prevention and Tobacco Control Act granted 
the US Food and Drug Administration (FDA) regulatory authority over cigarettes and 
other tobacco products (111th Congress, 2009).  That legislation includes the authority 
to reduce the maximal nicotine content of cigarettes, though not completely eliminate 
nicotine, if doing so benefits public health.  This policy is based on the overwhelming 
scientific evidence that nicotine is the constituent in cigarette smoke that promotes 
repeated use and eventual addiction (Stolerman & Jarvis, 1995; US Department of Health 
and Human Services, 2014) and the decades of research demonstrating that reducing the 
amount of nicotine in cigarettes reduces their addiction potential (Benowitz & 
Henningfield, 2013; Boren, Stitzer, & Henningfield, 1990; Shahan, Bickel, Madden, & 
Badger, 1999).  Thus, reductions in nicotine content may reduce smoking prevalence and 
related disease by disrupting initiation of smoking by new users and increasing cessation 
rates among current smokers.  Well-controlled studies have demonstrated that use of 
reduced nicotine content cigarettes (RNCCs) in the general smoker population is 
associated with reductions in smoking rates, nicotine exposure, dependence and toxicant 
exposure, as well as increases in smoking abstinence (Benowitz et al., 2007, 2009; 
Donny, Houtsmuller, & Stitzer, 2007; Donny et al., 2015; Hatsukami, Hertsgaard et al., 
2013; Hatsukami, Kotlyar et al., 2010).  Further, in a recently published report, 
simulation modeling was used to estimate the effect of a national nicotine reduction 
policy on the prevalence of tobacco use, tobacco-related mortality and life-years gained 
(Apelberg et al., 2018).  Not only would lowering the nicotine content of cigarettes lead 
to substantial reductions in tobacco use and smoking-related mortality, but the authors 
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projected that such a policy would result in 5 million additional adult smokers quitting 
smoking by 2020. 
While these data are promising, the prior studies on RNCCs have excluded 
individuals with SUDs and non-SUD psychiatric disorders and instead focused on stable, 
generally “healthy” smokers.  Considering their suboptimal response to standard 
smoking cessation treatments and substantial burden experienced from smoking, it is 
important to understand whether smokers with concurrent SUDs or other vulnerabilities 
may respond differently to RNCCs.  Indeed, the US FDA’s Center for Tobacco Products 
has identified these smokers as a priority population in whom more tobacco regulatory 
research is needed (US Department of Health and Human Services, 2017).  With regard 
to opioid-dependent smokers specifically, given the scientific evidence that opioid 
agonist medications may increase the reinforcing effects of nicotine administration 
(Chait & Griffiths, 1984; Mello, Lukas, & Mendelson, 1985; Mello, Mendelson, Sellers, 
& Kuehnle, 1980), it is critical to ensure that these smokers will not compensate for 
reduced nicotine levels by increasing their smoking rates or experience a unique profile 
of subjective effects following use of RNCCs.  Tobacco withdrawal is a subjective effect 
with direct implications for the potential acceptability and safety of RNCCs among 
consumers (Donny et al., 2014).  While promising data suggest that RNCCs may 
attenuate tobacco withdrawal severity (Table 1), very little is known about the ability of 
RNCCs to attenuate tobacco withdrawal severity in smokers with co-occurring other 




1.5. Evaluating RNCCs among Vulnerable Smokers  
To our knowledge, only two studies have evaluated tobacco withdrawal among 
vulnerable smoker populations and only one of those included participants with SUDs.  
In an initial small, within-subject study, the effects of smoking a reduced nicotine 
cigarette, nicotine replacement therapy, and a usual brand cigarette were examined 
among individuals with schizophrenia (n=30) versus those without a psychiatric disorder 
(n=26) (Tidey, Rohsenow, Kaplan, Swift, & Ahnallen, 2013).  While participants with 
schizophrenia reported greater tobacco withdrawal severity compared to those without 
psychiatric disorders across all study conditions, the RNCC was as effective at 
attenuating tobacco withdrawal symptoms as participants’ usual brand cigarette.  
The second and more recent study was completed by our research group (Higgins 
et al., 2017).  To our knowledge, this has been the only trial to date to examine the acute 
effects of cigarettes varying in nicotine content among opioid-maintained smokers.  
Using a multi-site, double-blind, within-subject design, we sought to investigate the acute 
effects of RNCCs among three populations of vulnerable smokers (N=169): opioid-
maintained individuals (n=60), individuals with affective disorders (n=56), and 
socioeconomically-disadvantaged women of childbearing age (n=53).  Across 14 
outpatient laboratory sessions, participants were acutely exposed to research cigarettes 
containing nicotine doses that ranged from levels below the proposed addiction threshold 
(Benowitz & Henningfield, 1994) to those consistent with commercially available 
cigarettes (i.e., 0.4, 2.4, 5.2, and 15.8 mg/g of tobacco), as well as to their usual brand 
cigarette.  All study sessions were conducted following a brief period of smoking 
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abstinence (approximately 6-8 hours of abstinence or breath carbon monoxide levels 
<50% of baseline).    
The relative reinforcing effects of smoking (i.e., addiction potential) decreased as 
an orderly function of decreasing the nicotine content of cigarettes in all three vulnerable 
populations.  In terms of the withdrawal severity experienced and, importantly, the extent 
to which RNCCs attenuated smokers’ withdrawal following acute abstinence, all nicotine 
doses significantly reduced tobacco withdrawal severity, with higher magnitude 
reductions seen at the higher dose cigarettes.   
The primary outcomes in that study (e.g., reinforcing efficacy as evaluated by 
concurrent choice preference testing and behavioral economic simulation tests, 
compensatory smoking) were reported in aggregate across the vulnerable smoker sub-
groups examined given the similarities among smoker groups on those measures.  With 
regard to withdrawal, while opioid-maintained smokers reported levels of tobacco 
withdrawal that were higher than the socioeconomically-disadvantaged women and 
similar to smokers with affective disorders, how tobacco withdrawal severity changed 
over time among opioid-maintained (OM) smokers and whether there were differences 
in withdrawal as a function of the nicotine doses were not examined.  Additionally, how 
the other characteristics representative of vulnerability to smoking (e.g., depression, 
educational attainment) may affect withdrawal severity and contribute to OM smokers’ 






We sought to comprehensively evaluate tobacco withdrawal severity in response 
to acute exposure to RNCCs among OM smokers under conditions of double-blind 
nicotine administration, acute abstinence and across multiple nicotine doses.  Our 
overarching aim was to better understand the ability of cigarettes varying in nicotine 
content to attenuate tobacco withdrawal severity in OM compared to non opioid-
maintained (NOM) smokers.   
In Aim 1, we examined the association between OM status (i.e., opioid-
maintained participants vs. all other study participants) and tobacco withdrawal in 
response to participants’ usual brand cigarette.  We hypothesized that OM smokers would 
experience greater severity of tobacco withdrawal than NOM smokers.   
In Aim 2, we examined the association between OM status and tobacco 
withdrawal in response to the four research cigarette doses (0.4, 2.4, 5.2, 15.8 mg/g) 
under double-blind conditions.  We hypothesized that OM status would moderate the 
relationship between nicotine dose and withdrawal severity.  Specifically, we anticipated 
that higher nicotine dose research cigarettes would reduce tobacco withdrawal severity 
to a greater extent among NOM smokers vs. OM smokers.  
As an exploratory Aim 3, we also examined the contribution of other 
characteristics previously associated with smoking vulnerability (e.g., depression, 
anxiety, education level) on acute withdrawal in response to cigarettes varying in nicotine 
content, as well as how each vulnerability was associated with tobacco withdrawal over 
and above OM status.  This research question stemmed in part from the previously-
discussed observation of sub-group differences in tobacco withdrawal severity in the 
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parent trial in which more severe withdrawal was seen among OM smokers and those 
with affective disorders relative to disadvantaged women (Higgins et al., 2017) (Figure 
1), suggesting that project-specific inclusion criteria such as anxiety, depression and 
education level were particularly important to consider.  It also drew from the larger 
literature showing that non-SUD psychiatric disorders (e.g., mood, anxiety, personality 
disorders) and socioeconomic disadvantage (e.g., level of educational attainment) are not 
only independently associated with elevated smoking prevalence and lower quit rates 
compared to the general population, but also co-occur at high rates in populations with 
OUD (Higgins, 2016; Higgins & Chilcoat, 2009; Hiscock et al., 2012; Lasser et al., 2000; 
Parsells, Kelly et al., 2008; SAMHSA, 2015; Schroeder, 2016; Strain, 2002; US 
Department of Health and Human Services, 2014).  Further, relevant to tobacco 
withdrawal specifically, there is strong evidence in the literature that non-SUD 
psychiatric disorders are associated with a greater incidence and severity of tobacco 
withdrawal (Covey, Glassman, & Stetner, 1990; Morrell, Cohen, & al’Absi, 2008; 
Pomerleau, Marks, & Pomerleau, 2000; Smith, Homish, Giovino, & Kozlowski, 2014; 
Weinberger et al., 2010).  Emerging research has also suggested that this pattern of 
elevated withdrawal severity may extend to those with socioeconomic disadvantage 
(Harwood, Salsberry, Ferketich, & Wewers, 2007; Hiscock et al., 2012; Marmot & 
Wilkinson, 2005; Wiltshire, Bancroft, Parry, & Amos, 2003).  Considering the potential 
synergistic interaction among risk factors that may influence tobacco withdrawal severity 
in OM smokers, in Aim 3, we examined how OM status may contribute to withdrawal in 
the larger context of other smoking-related vulnerabilities that so often co-occur in 
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opioid-dependent smokers.  As this represented an exploratory aim, we did not propose 
a directional hypothesis for this outcome. 
 
1.7. Summary 
 Taken together, we are at a critical moment in tobacco regulatory science and 
tobacco control with the FDA actively considering reducing the nicotine levels of 
cigarettes as a national harm reduction policy.  Scientific efforts are urgently needed to 
understand the impact of such a nicotine reduction policy on the populations of smokers 
with co-occurring vulnerabilities that smoke the majority of the cigarettes in the US 
(Lasser et al., 2000).  An improved understanding of the ability of reduced nicotine 
cigarettes to attenuate tobacco withdrawal in opioid-maintained smokers stands to 
directly inform FDA policy decisions and advance efforts to reduce the disproportionate 
burden of smoking in this population. 
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CHAPTER 2: METHODS 
2.1. Participants 
Participants were 202 daily smokers (65 with affective disorders, 66 with OUD, 
71 socioeconomically-disadvantaged women).  Participants were recruited though 
advertisements placed on Facebook, bulletin boards throughout the community, buses 
and local newspapers at Johns Hopkins University, Brown University and the University 
of Vermont.  The study was approved by the respective universities’ Institutional Review 
Boards, and all participants provided written informed consent.  Parent study inclusion 
criteria required that participants were >18 years of age, reported smoking >5 cigarettes 
per day for the past year and provided an expired breath carbon monoxide (CO) level of 
>8 particles per million (ppm).  All participants had to provide a negative urine 
toxicology test for illicit drugs other than marijuana.  Exclusion criteria included an 
intention to quit smoking within the next 30 days, significant use (>9 days) of other 
tobacco products in the past 30 days, currently pregnant or trying to become pregnant, 
breastfeeding, exclusive use of “roll your own” cigarettes, or current suicidal ideation or 
a recent suicide attempt.  
Additionally, there were several additional project-specific inclusion (Figure 2) 
and exclusion criteria.  Participants in the OM smokers project were females and males 
ages 18-70 who were currently receiving methadone or buprenorphine maintenance 
treatment.  They were required to be stable on their maintenance dose which was defined 
as no change in dose and <30% urine toxicology samples testing positive for illicit drug 
use in the past month.  Participants in the affective disorders project were females and 
males ages 18-70 years who met criteria for current or past year major depressive 
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disorder, dysthymic disorder, generalized anxiety disorder, post-traumatic stress 
disorder, obsessive compulsive disorder, specific phobia or panic disorder with or 
without agoraphobia based on the MINI International Neuropsychiatric Interview for 
DSM-IV (Sheehan et al., 1998).  Finally, participants in the project with 
socioeconomically-disadvantaged women were females, ages 18-44, with less than an 
associate’s degree.   
 
2.2. Research Cigarettes 
Research cigarettes were manufactured by the 22nd Century Group (Clarence, 
NY) and included four nicotine content dose conditions: 0.4, 2.4, 5.2, and 15.8 
milligrams of nicotine per gram (mg/g) of tobacco (Donny et al., 2015; Higgins et al., 
2017).  The research cigarettes were identical in appearance to one another and to 
commercially-available cigarettes but varied in nicotine content.  The 15.8 mg/g cigarette 
was designed to have a nicotine content similar to commercially available cigarettes, the 
0.4 mg/g cigarette fell below the hypothesized threshold of addiction (Benowitz & 
Henningfield, 1994), and the 5.2 and 2.4 mg/g cigarettes represented reduced nicotine 
content cigarettes.  All sessions involving research cigarettes took place under double-
blind conditions with each cigarette dose being represented by a letter code for blinded 
research staff.   
 
2.3. Procedures 
The parent study consisted of 14 experimental sessions using a within-subject 
design.  All sessions were conducted under conditions of brief smoking abstinence 
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(breath CO<50% of baseline).  Participants were instructed to abstain from smoking for 
at least six to eight hours prior to the session so as to meet the breath CO criteria.  At the 
start of each session, participants took two puffs from their usual brand cigarette in order 
to equate the time since last cigarette across study participants (Henningfield & Griffiths, 
1981).  Thirty minutes following the two puffs marked the beginning of the experimental 
session.  During this 30-minute break participants completed the Minnesota Tobacco 
Withdrawal Scale (MTWS; Hughes & Hatsukami, 1986; described in greater detail 
below) and the Questionnaire on Smoking Urges-Brief (QSU; Cox, Tiffany, & Christen, 
2001) to assess baseline levels of tobacco withdrawal and craving, respectively, prior to 
exposure to the research cigarettes.  The 14 study sessions were divided into three study 
phases.  As Phase 1 is the focus of this project, Phases 2 and 3 will only be described 
briefly here (Higgins et al., 2017). 
Study Intake Visit (Session 0).  Participants presented for an in-person screening 
visit to determine their eligibility.  Intake screening measures relevant to this dissertation 
included smoking and demographic characteristics (e.g., average cigarettes smoked per 
day, cigarette dependence severity, education level, gender, age).  The Fagerström Test 
for Cigarette Dependence (FTCD) is a 7-item measure to assess cigarette dependence 
with total scores reported as the sum of scores on the first 6 items of the measure 
(Fagerström, 2012).  Higher scores are suggestive of higher levels of dependence. The 
Beck Depression Inventory (BDI; Beck, 1996) and the Overall Anxiety Severity and 
Impairment Scale (OASIS; Norman, Cissell, Means-Christensen, & Stein, 2006) were 
used to assess depression and anxiety, respectively.  The BDI is a 21-item measure which 
screens for depression severity in the past two weeks.  Items are rated on a 0-3 scale with 
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total scores ranging from 0 to 63.  A total score is computed based on summing scores 
on all items of the measure.  Research suggests that a valid BDI cut-off to use in the 
research setting is a score of 17 or greater which is indicative of clinically meaningful 
depression and a potential need for treatment (Beck, 1996; Sprinkle et al., 2002).  The 
OASIS is a 5-item screening measure assessing anxiety severity in the past week.  Items 
are rated on a 0-4 scale with total scores ranging from 0 to 20.  Finally, OM smokers also 
provided additional information on their opioid maintenance medication (e.g., 
methadone or buprenorphine, current dose).   
Baseline Session (Session 1) and Study Phase 1 (Experimental Sessions 2-5).  
           Session 1 (i.e., baseline session) served as an orientation or practice session 
wherein participants smoked their usual brand cigarette using the study procedures that 
would be in place for remaining sessions.  Thereafter during Sessions 2-5, participants 
sampled each research cigarette under double-blind, acute abstinence conditions with 
cigarettes presented in a random order (Figure 3).  Participants smoked one of the four 
research cigarettes per session in a random order.  In all sessions, participants were 
instructed to smoke the research cigarettes as they would smoke their usual brand 
cigarette, but to do so through a plastic cigarette holder connected to a device that 
recorded measures of smoking topography (Lee, Malson, Waters, Moolchan, & 
Pickworth, 2003).   
After smoking the cigarette, participants then completed a battery of self-reported 
measures including the Cigarette Purchase Task (CPT; MacKillop et al., 2008), Modified 
Cigarette Evaluation Questionnaire (mCEQ; Cappelleri et al., 2007), QSU and MTWS, 
which measure hypothetical cigarette purchasing behavior, the degree to which people 
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experience the reinforcing effects of cigarettes, cigarette craving and tobacco withdrawal, 
respectively.  The MTWS and the QSU were administered to participants every 15 
minutes for an hour following the completion of the research cigarette in each session.  
At each 15-minute timepoint, research staff also measured expired breath CO levels using 
a hand-held device (CoVita, Haddonfield, NJ). 
Study Phases 2 and 3.  As noted above, Phases 2 and 3 were not a focus of this 
dissertation and thus are only briefly described here.  During Phase 2 (Sessions 6-11), 
the relative reinforcing effects of the range of nicotine doses were evaluated using a 
concurrent choice testing paradigm, in which participants were instructed to choose 
which cigarette they preferred to smoke when both cigarettes were available at an equal 
response cost.  In Phase 3 (Sessions 12-14), participants chose between cigarette dose 
pairs, with a focus on the highest and the lowest dose cigarettes.  The highest dose 
cigarette had a higher response cost and was available on an increasing progressive ratio 
schedule.     
 
2.4. Outcome Measures 
The primary outcome measure was the Minnesota Tobacco Withdrawal Scale 
(MTWS; Hughes & Hatsukami, 1986), a 15-item self-report measure of tobacco 
withdrawal.  Each item is rated on a 5-point ordinal scale (0=none, 1=slight, 2=mild, 
3=moderate, 4=severe).  The MTWS includes seven DSM-5 items (anger/irritability/ 
frustration, anxiety/nervousness, difficulty concentrating, impatience/restlessness, 
increased appetite/hunger, insomnia/awakening at night, depressed mood/sad) that are 
averaged to construct a single withdrawal severity score (i.e., MTWS Total score).  
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Additionally, a Desire to Smoke item is typically analyzed separately as a measure of 
craving (Hughes & Hatsukami, 1998).  The scientific literature supports the reliability 
and validity of the MTWS in measuring withdrawal and craving severity in the general 
smoker population (Cappelleri et al., 2005; Etter & Hughes, 2006; Hughes, 2007; Javitz, 
Lerman, & Swan, 2012; Piper, 2015; Piper, McCarthy, & Baker, 2006; Toll, O’Malley, 
McKee, Salovey, & Krishnan-Sarin, 2007; Weinberger et al., 2007; West, Ussher, Evans, 
& Rashid, 2006).  
During each session, the MTWS was administered following acute (i.e., 6-8 
hours) abstinence and after taking the two puffs of the usual brand cigarette (Time 0; Pre-
smoking baseline).  MTWS administration was then repeated every 15 minutes for an 
hour following completion of the assigned research cigarette (Times 1-4).  The dependent 
variables for this dissertation were the MTWS Total and Desire to Smoke scores across 
these five timepoints (Times 0-4) during the baseline session and Phase 1 of the study 
(Figure 3).   
 
2.5. Statistical Analyses 
This secondary analysis focused on participants who completed Phase 1 of the 
parent study (N=202).  Of these, we excluded two participants as one participant had 
missing BDI and OASIS data from baseline and another participant had missing OASIS 
data at baseline (N=200).  While one participant had missing MTWS data at a single 
timepoint for one session (45-minute point in Session 1), they were still included in the 
analyses.  
Demographic, psychiatric and smoking characteristics were examined by OM 
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status using chi-square or Fisher’s Exact tests for categorical variables and t-tests or 
Wilcoxon Rank Sum tests for continuous variables.  To address Aim 1, MTWS Total 
scores and Desire to Smoke scores were examined during Session 1 (usual brand cigarette 
baseline session) using mixed-model repeated-measures (RM) analyses.  Time (i.e., pre-
smoking baseline and 15, 30, 45, and 60 minutes post-smoking the cigarette) was 
included in the model as a within-subject factor and OM status, dichotomized (yes vs 
no), was included as an across-subject factor.  Study site was included as a random factor 
in this model.    
For Aim 2, we similarly performed a mixed-model RM analysis.  Time (i.e., pre-
smoking baseline and 15, 30, 45, and 60 minutes after smoking the cigarette) and research 
cigarette dose (0.4, 2.4, 5.2, 15.8 mg/g) were included as within-subject factors and OM 
status as an across-subject factor.  Study site was included as a random effect in this 
model.   
In exploratory Aim 3, we examined the contribution of participant characteristics 
reflective of smoking vulnerability to tobacco withdrawal using multivariable mixed-
model RM analyses.  As with Aim 2, time and nicotine dose were within-subject factors 
and OM status was an across-subject factor.  Variable selection for construction of the 
final model was based on both bivariate testing and the empirical literature.  Age, race, 
gender, employment status, marital status, FTCD total score, cigarettes smoked per day, 
BDI and OASIS were included in preliminary models as there was evidence that they 
were associated with withdrawal based on bivariate testing (p<.10).  Education level, age 
started smoking regularly and screening CO level were forced into preliminary models 
based on the literature.  We chose to use a dichotomous variable for BDI in our models 
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for ease of interpretation using a commonly established cut-off of 17 to distinguish those 
with clinically meaningful depression levels (Beck, 1996; Sprinkle et al., 2002).  
Furthermore, in preliminary models, we forced OM status into models and added 
additional characteristics sequentially to determine how each was associated with 
tobacco withdrawal over and above OM status.  We present final multivariable models 
in two ways: First, with only the variables that were significant predictors of tobacco 
withdrawal; second, with all significant predictors of withdrawal with OM status retained 
in the model, regardless of significance, as it was a main focus of the current study.   
Finally, supplemental analyses were conducted to examine changes in withdrawal 
and craving in response to nicotine dose, using methods commonly employed in 
behavioral pharmacology research (e.g., Iversen & Lattal, 1991; Sobel, Sigmon, & 
Griffiths, 2004).  First, we examined peak effects of the research cigarette nicotine doses’ 
ability to attenuate withdrawal. Specifically, for Aims 1 and 2, we computed the peak 
change from baseline in withdrawal (i.e., difference between the pre-smoking baseline 
timepoint and the minimum withdrawal score seen between 15 and 60 minutes post-
smoking) for each participant, then averaged across participants to form the dependent 
measure in mixed models.  In these models, OM status was the primary independent 
variable and, for Aim 2, dose was also included in the model.  Second, sensitivity 
analyses were conducted for Aims 2 and 3, examining area under the time curve (AUC) 
of repeated MTWS scores as the dependent variable to determine whether AUC analysis 
differs from repeated measures mixed modeling in explaining withdrawal scores over 
time.  Finally, we compared data from participants who completed Phase 1 of the study 
 22 
and were included in this secondary analysis (n=200) to those who dropped out (n=35) 
on our variables of interest to determine any potential biases due to attrition. 
All post-hoc testing used a Bonferroni adjustment for multiple comparisons.  All 
analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).  Statistical 
significance was defined as p<.05.   
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CHAPTER 3: RESULTS 
3.1. Participant Characteristics 
 Baseline demographic and smoking characteristics by OM status are presented in 
Table 2.  Briefly, OM smokers were on average 41 years of age, 23% unemployed, 
smoked an average of 16 cigarettes per day and presented with an FTCD score of 5, 
suggesting moderate tobacco dependence.  Compared to NOM smokers, OM smokers 
were older, less likely to be female, more likely to be nicotine dependent, and had lower 
levels of anxiety and depression.  Employment and marital status were also significantly 
different between the groups.  
 
3.2. Aim 1 
Mean tobacco withdrawal severity scores (i.e., MTWS Total scores) during the 
baseline (usual brand cigarette) Session 1 did not differ as a function of OM status (F(1, 
185)=0.69, p=.41; Figure 4, upper panel).  There also was no evidence of an interaction 
between OM status and time on mean withdrawal scores during the baseline session (F(4, 
791)=1.48, p=.21).   
A similar pattern was seen with cigarette craving (i.e., the Desire to Smoke item 
of the MTWS).  Craving severity following smoking the usual brand cigarette did not 
differ as a function of OM status (F(1, 198)=0.19, p=.66; Figure 4, lower panel), nor was 
there a significant interaction between OM status and time on reports of cigarette craving 
(F(4, 791)=1.53, p=.19).   
For both withdrawal and craving, there was a significant main effect of time (F(4, 
795)=52.80, p<.001; F(4, 795)=62.82, p<.001, respectively) with MTWS scores 
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decreasing 15 minutes after smoking the usual brand cigarette and then gradually 
increasing over time (i.e., across the remaining 45 minutes of the hour following 
smoking). 
 
3.3. Aim 2 
 When examining tobacco withdrawal during exposure to cigarettes varying in 
nicotine content during Sessions 2-5, withdrawal severity did not differ as a function of 
OM status (F(1, 175)=1.65, p=.20; Figure 5, upper panel).  There also was no significant 
interaction on the withdrawal outcome between OM status and nicotine dose (F(3, 
591)=2.15, p=.09) or among OM status, time and nicotine dose (F(19, 3146)=1.35, 
p=.14).   
Similarly, there was no main effect of OM status on craving (F(1, 198)=2.76, 
p=.10), no OM by nicotine dose interaction (F(3, 591)=2.34, p=.07), and no OM status 
by time by nicotine dose interaction (F(19, 3146)=1.57, p=.06)(Figure 5, lower panel).   
Consistent with the parent trial report (Higgins et al., 2017), there were significant 
dose x time interactions on both withdrawal and craving severity in Phase 1 (F(12, 
2386)=3.00, p<.001; F(12, 2385)=6.42, p<.001, respectively) with both outcomes 
decreasing over time following smoking the research cigarettes and then gradually 
returning to baseline levels over time, with higher magnitude reductions seen at higher 
dose cigarettes.  Finally, there were also main effects of dose and time for both 
withdrawal and craving measures (MTWS Total score: Dose F(3, 591)=4.5, p<.001, time 
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F(4, 793)=83.62, p<.001; MTWS Desire to Smoke: Dose F(3, 591)=7.04, p<.001, time 
F(4, 793)=130.93, p<.001). 
 
3.4. Exploratory Aim 3 
 In exploratory Aim 3, we examined the contribution of OM status in relation to 
other participant characteristics reflective of smoking vulnerability to tobacco 
withdrawal and craving.  Regarding withdrawal during the baseline Session 1 (i.e., usual 
brand cigarette session), time, BDI and FTCD, but not OM status, were significantly 
associated with tobacco withdrawal severity (Table 3, upper right panel).  In a final model 
that only included significant predictors of withdrawal severity, time, BDI score and 
FTCD total score were significant predictors in this usual brand cigarette session (Table 
3, upper left panel).  In these models, individuals with clinically meaningful depression 
(i.e., BDI total score >17) evidenced greater levels of withdrawal severity compared to 
those without clinically elevated depression (i.e., BDI total score <17) (mean 
difference=0.60; p<.001).  Similarly, those with higher levels of baseline cigarette 
dependence as measured by the FTCD also evidenced greater withdrawal severity (β(SE) 
=0.06 (0.02), p<.01) in response to the usual brand cigarette. 
 During Sessions 2-5 evaluating research cigarettes with varying nicotine content, 
the significant predictors of withdrawal were nicotine dose, time, the dose x time 
interaction, BDI, education level, race, FTCD total score and OM status (Table 3, lower 
right panel).  While OM status was a significant predictor of withdrawal in this model 
(F(1,191)=6.65; p=.01), it was subsequently dropped from the final model as there was 
evidence of confounding between OM status and BDI.  Specifically, not only was OM 
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status not a significant predictor of withdrawal in any of the prior models, but there were 
significant correlations between BDI scores and OM status (Spearman correlation=  
-0.26, p<.001).  With regards to differences by race, Non-Latino White participants had 
higher withdrawal than Non-Latino Black participants (mean difference=0.39; p=0.01).  
The resulting final model predicting withdrawal included nicotine dose, time, the dose x 
time interaction, BDI, FTCD scores, and education level (Table 3, lower left panel).  In 
this model, higher depression at baseline (mean difference=0.64, p<.001) and higher 
cigarette dependence (β(SE)=0.07(0.02), p<.01) were predictive of greater tobacco 
withdrawal.  Lower educational attainment (i.e., high school education vs. some college 
and some college vs. associate’s degree or higher) also predicted greater withdrawal in 
response to the cigarettes varying in nicotine content (mean differences=0.29 and 0.33, 
respectively; p’s<.05).  
 With regard to craving, time, BDI, FTCD and screening CO level, but not OM 
status, were significantly associated with craving during the baseline Session 1 (i.e., usual 
brand cigarette session) (Table 4, upper right panel).  The final model of variables 
significantly predicting craving during this session included time, BDI, FTCD and 
screening breath CO level (Table 4, upper left panel).  Higher baseline levels of 
depression (mean difference=0.32, p=0.01), cigarette dependence (β(SE)=0.14 (0.03); 
p<.001) and breath CO levels at study intake (β(SE)=0.02 (0.01); p<.01) were predictive 
of greater craving severity. 
Finally, in terms of craving during exposure to cigarettes varying in nicotine 
content, significant predictors of craving were nicotine dose, time, dose x time 
interaction, FTCD total score, the OM status x time interaction, but not OM status (Table 
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4, lower panel).  The significant interaction between time and OM status was primarily 
driven by between-group differences in mean craving at the last time point (i.e., an hour 
after smoking the research cigarette) (adjusted means=2.95 vs. 2.63 for OM vs. NOM, 
respectively; p=.04); however, none of the comparisons of means at each timepoint 
between groups differed after Bonferroni adjustment (p’s=1.0), suggesting that 
confounding of multiple comparisons may have driven the significant interaction seen in 
the final model.  
 
3.5. Additional Analyses 
As previously noted, several additional analyses were conducted to examine peak 
change from the pre-smoking baseline timepoint for withdrawal and craving in baseline 
Session 1 and across Sessions 2-5.  We also examined AUC analyses to validate the 
results from mixed modeling.  Finally, to address attrition, we compared those who did 
and did not complete Phase 1 on our variables of interest to determine any potential biases 
due to attrition.  
When examining peak change from the pre-smoking baseline timepoint during 
baseline Session 1 (related to Aim 1), there were no differences by OM status for MTWS 
Total scores (F(2, 197)=0.41, p=.52) or Desire to Smoke (F(2, 197)=0.06, p=.81).  A 
similar pattern was observed when examining peak change during Sessions 2-5 (related 
to Aim 2), with no differences by OM status for MTWS Total scores (F(1, 198)=0.56, 
p=.46) or Desire to Smoke (F(1, 198)=0.11, p=.75).  There were main effects of nicotine 
dose on peak change in MTWS Total (F(3, 595)=4.04, p<.001) and Desire to Smoke 
 28 
scores (F(3, 595)=14.17, p<.001), with higher nicotine doses resulting in a larger 
magnitude reduction in MTWS scores from the pre-smoking baseline timepoint. 
Regarding AUC analyses across the multiple nicotine doses evaluated in Sessions 
2-5, there was neither an effect of OM status (F(1, 171)=1.68, p=.20) nor an OM status 
by nicotine dose interaction (F(3, 587)=2.37, p=.07) on MTWS Total score AUC.  There 
also were no main effects of OM status on Desire to Smoke AUC (F(1, 198)=2.61, 
p=.11), though there was a significant OM status by nicotine dose interaction (F(3, 
587)=2.85, p=.04).  Upon probing this interaction, we determined that it was primarily 
driven by between-group differences in mean craving AUC at the 5.2 mg/g cigarette 
(adjusted means=10.67 vs. 8.83 for OM vs. NOM, respectively; p=.01)(Figure 5); 
however, this difference was no longer significant after Bonferroni adjustment for 
multiple comparisons (p=.15).  Thus, overall, AUC analyses produced similar results to 
the repeated measures mixed model analyses, with no robust effects of OM status on 
tobacco withdrawal or craving scores via the MTWS.  In both models predicting tobacco 
withdrawal and craving AUC in Phase 1, there were main effects of nicotine dose (F(3, 
587)=4.74, p<.01; F(3, 587)=8.73, p<.001, respectively) consistent with repeated 
measures mixed model analyses. 
Additional analyses for exploratory Aim 3 used AUC to examine tobacco 
withdrawal and craving in the above multivariable models and produced similar results 
to repeated measures mixed modeling, again suggesting that OM status does not 
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contribute significantly to withdrawal or craving across usual brand cigarettes or 
cigarettes varying in nicotine content (Table 5).   
Finally, our completer analysis suggested that individuals who did (n=200) vs. did 
not (n=35) complete Phase 1 were similar on nearly all demographic and smoking 
characteristics with the exception of higher cigarettes smoked per day reported at study 
intake among individuals who did not vs. did complete Phase 1 (means=18 vs. 15 average 
cigarettes/day, respectively; p=.05) (Table 6).  
 30 
CHAPTER 4: DISCUSSION 
4.1. Effects of Opioid Maintenance and Other Vulnerabilities on  
Tobacco Withdrawal 
Smokers with concurrent opioid use disorder have an extremely high prevalence 
of smoking, experience poor cessation outcomes, and bear a disproportionate burden of 
smoking-related adverse health consequences.  This is a subgroup of smokers for whom 
novel harm reduction paradigms are urgently needed to reduce the burden of smoking.  A 
promising national policy is currently under consideration by the FDA to decrease the 
nicotine content of cigarettes in an effort to reduce smoking prevalence and smoking-
related disease (111th Congress, 2009; Gottlieb & Zeller, 2017).  However, data have 
suggested that OM smokers may experience a unique response to nicotine including 
heightened reinforcement and potentially more severe withdrawal when stopping smoking 
(Chait & Griffiths, 1984; Story & Stark, 1991; Weinberger et al., 2010).  Thus, it is critical 
to understand the extent to which reduced nicotine cigarettes may attenuate tobacco 
withdrawal severity in this vulnerable smoker group as this has direct implications for the 
potential acceptability and uptake of reduced nicotine cigarettes in OM smokers. 
Across usual brand and reduced nicotine cigarettes, tobacco withdrawal and 
craving did not differ as a function of OM status.  While these results are inconsistent with 
our hypotheses that OM status would moderate the relationship between nicotine dose and 
withdrawal severity, they are consistent with our recent study examining tobacco 
withdrawal severity in OM vs. non-SUD smokers in which no differences in withdrawal 
or craving severity were observed between groups across a 2-week period of 
biochemically-verified smoking abstinence (Streck et al., 2018).  Whereas the prior 
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investigation examined individuals who quit smoking their usual brand cigarettes for a 2-
week study period, the current study further extends that work by including an evaluation 
of multiple nicotine doses, rigorous double-blind conditions, and smokers who were not 
currently interested in quitting smoking.  The finding that OM smokers did not experience 
greater tobacco withdrawal or craving relative to other vulnerable populations without 
concurrent opioid dependence suggests that a national nicotine reduction policy would not 
produce untoward withdrawal-related effects in this important smoker group.  
In exploratory analyses, we also examined several other characteristics reflective 
of smoking vulnerability (e.g., depression, nicotine dependence, educational attainment) 
and their contributions to tobacco withdrawal and craving severity.  Generally, the 
strongest predictor of both withdrawal and craving was baseline depression, with clinically 
meaningful depression at study intake consistently associated with increased withdrawal 
and craving across all nicotine doses.  Once again, OM status did not exert a meaningful 
influence on withdrawal or craving when accounting for other vulnerabilities.  These 
findings are consistent with prior research showing elevated incidence and severity of 
tobacco withdrawal among smokers with affective disorders, particularly depression 
(Covey et al., 1990; Morrell et al., 2008; Pomerleau et al., 2000; Smith et al., 2014; 
Weinberger et al., 2010).  Also worth noting is that negative affect is a strong contributor 
in both depression and tobacco withdrawal (Tonkin et al., 2018), and depressed 
mood/sadness is an item on the MTWS.  Our data are also consistent with the only other 
prior study to our knowledge which has examined the effects of depressive symptoms on 
tobacco withdrawal in response to RNCCs (Tidey et al., 2017).  In that study, which was 
conducted with generally healthy smokers, while there were no interactions between 
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nicotine dose and depression on withdrawal, greater withdrawal severity was observed 
across nicotine doses in participants with higher levels of depression.  Overall, given the 
high rates of concomitant depression and other psychiatric disorders among OM patients 
(Barry et al., 2016; Kidorf et al., 2004; Strain, 2002), these findings may hold clinical 
significance for efforts to tackle smoking cessation among OM patients with co-occurring 
psychiatric distress.  However, also important to note is that we did not see an additive 
effect on withdrawal severity of OM status and depression in this study.  This is actually 
consistent with a prior report using nationally-representative data to examine the effects of 
having a co-morbid psychiatric disorder and SUD compared to a psychiatric disorder alone 
on tobacco withdrawal (Weinberger et al., 2010).  In that study, while the presence of a 
SUD and a non-SUD psychiatric disorder were each independently associated with 
increased presence and severity of withdrawal symptoms, the two types of disorders did 
not act additively to increase withdrawal symptoms.  That study did not examine the effects 
of OUD specifically.  
Several comments are warranted on the other characteristics examined during the 
exploratory Aim 3 analyses.  First, in the multivariable models, anxiety was not a final 
significant predictor of withdrawal once depression was added to the model.  Prior studies 
have demonstrated an association between anxiety and increased incidence and severity of 
tobacco withdrawal (Breslau et al., 1992; Morrell et al., 2008; Weinberger et al., 2010; 
Zvolensky et al., 2008).  It is possible that the instrument selected to measure anxiety in 
this study (i.e., OASIS) may have been less sensitive than those used in prior studies on 
this topic.  For example, while the OASIS is a widely used and accepted screening measure 
for anxiety, the four studies above demonstrating a significant association between anxiety 
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and tobacco withdrawal used other measures (e.g., Anxiety Disorders Interview Schedule, 
National Institute of Mental Health Diagnostic Interview Schedule).  Thus, it is possible 
that future studies evaluating anxiety and RNCC-associated withdrawal severity in OM 
smokers with other instruments may find a more robust association. 
Second, lower educational attainment was associated with more severe tobacco 
withdrawal across nicotine doses.  Limited educational attainment has been identified as 
an important proxy for socioeconomic disadvantage (Shavers, 2007) and is associated with 
increased prevalence of smoking and smoking-related adverse consequences (Agaku, 
King, Dube, & Centers for Disease Control and Prevention, 2014; Jamal, 2016; King, 
Dube, & Tynan, 2012).  Several prior reports have hypothesized that withdrawal may be 
greater among those with socioeconomic disadvantage more generally (Harwood et al., 
2007; Hiscock et al., 2012; Marmot & Wilkinson, 2005; Wiltshire et al., 2003), though we 
are aware of only two empirical investigations on this topic.  In the first study, Breslau and 
colleagues examined epidemiological data from young adults in one state and found no 
effects of education level on tobacco withdrawal (Breslau et al., 1992).  In the second, 
which was conducted in Syria, the authors reported that higher educational attainment was 
associated with lower withdrawal scores among patients enrolled in a smoking cessation 
trial (Ben Taleb et al., 2016).  To our knowledge, the present study is the first to report on 






4.2. Limitations and Strengths 
Several limitations of this study are important to note.  First, we utilized an acute 
exposure paradigm wherein participants abstained from smoking for 6-8 hours (versus 
12-hour abstinence or longer), sampled each dose research cigarette during one 
laboratory session, and rated their withdrawal across one hour post-smoking (versus days 
or weeks).  As such, we did not examine the full timecourse of tobacco withdrawal during 
extended exposure, but rather the extent to which RNCCs may attenuate tobacco 
withdrawal severity under conditions of acute abstinence.  These acute-exposure data 
support the feasibility of a national nicotine reduction policy in OM and other vulnerable 
populations.  However, additional extended exposure studies are needed to determine if 
our results generalize to a longer timecourse of withdrawal under conditions of extended 
abstinence and prolonged exposure to these reduced nicotine cigarettes.  We are 
positioned to contribute new information on this question in the near future as we have 
an extended exposure (i.e., 12-week) trial currently underway examining the longer-term 
effects of RNCCs in OM and other vulnerable smoker populations.  A recent publication 
of a similar extended exposure trial in generally healthy smokers reported mild and 
temporary increases in certain withdrawal symptoms with the extended use of RNCCs 
(i.e., anger, irritability, frustration, increased appetite), but that these symptoms resolved 
by 6 weeks (Dermody et al., 2018).  Our forthcoming experimental study will extend 
upon these prior findings to specifically address withdrawal in response to extended 
exposure to RNCCs among vulnerable smokers.   
Second, to be eligible for the present study, participants were required to be stable 
in their opioid treatment, with limited opioid medication dose changes or illicit drug use.  
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It is possible that a less stable population with OUD, such as those not currently receiving 
treatment, may not respond as favorably to the RNCCs and that question merits further 
investigation.  A large number of individuals with OUD are not currently enrolled in 
opioid treatment (Saloner & Karthikeyan, 2015), and one study has reported higher levels 
of nicotine dependence and less motivation to quit among smokers not in opioid 
maintenance treatment (and actively using intravenous opioids) compared to those 
receiving treatment (Clarke et al., 2001).  As we observed a positive relationship between 
nicotine dependence and tobacco withdrawal in response to RNCCs, it is possible that 
smokers with OUD who are not stable in opioid treatment may experience greater 
withdrawal, though this is an empirical question that should be addressed more 
definitively in future studies.   
Third, this was a secondary analysis of data from a study that was not originally 
designed or intended to examine outcomes as a function of OM status; that is, the 
participant sample that was recruited for the parent study did not involve equal numbers 
of OM and NOM smokers or comparable sociodemographic characteristics (e.g., gender) 
across OM groups.  Although, we controlled for various sociodemographic 
characteristics that differed by OM status in multivariable analyses, that does not rule out 
the presence of other potential confounders.  Additionally, as the parent trial was entirely 
focused on understanding RNCC response among smokers with concomitant 
vulnerabilities (e.g., anxiety/depression, socioeconomic disadvantage), there was no 
control group of ‘healthy’ smokers without these co-occurring factors in the present 
analyses.   
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This study also had several important strengths.  First, this is the only study to 
date, to our knowledge, to rigorously evaluate tobacco withdrawal in response to RNCCs 
in OM smokers.  Second, study methodology included a rigorous, double-blind, highly 
controlled design, multiple nicotine doses, availability of multiple empirically-supported 
measures reflecting vulnerability to smoking, and minimal missing data or attrition.  
Third, it also is the first study to investigate the separate and combined effects of multiple 
co-occurring vulnerabilities (e.g., opioid dependence, depression, anxiety, 
socioeconomic disadvantage) and their impact on tobacco withdrawal severity in 
response to RNCCs.  Finally, this investigation is uniquely positioned to inform the 
FDA’s decision making around reduced nicotine content cigarettes and their safety and 
acceptability in vulnerable smoker populations as it moves toward the potential 
implementation of a national nicotine reduction policy.  
 
4.3. Conclusions 
Despite prior data suggesting that OM smokers may respond differently to 
nicotine and experience more severe withdrawal during reductions in nicotine intake, 
opioid-maintained smokers in this study responded favorably to reduced nicotine content 
cigarettes.  Specifically, under the conditions of acute exposure and abstinence evaluated, 
OM smokers did not experience more severe levels of tobacco withdrawal or craving 
relative to vulnerable smokers without concurrent opioid dependence.  Depression 
severity, rather than opioid dependence, was the strongest and most consistent predictor 
of withdrawal and craving severity among the characteristics examined.  These findings 
provide additional support for the potential beneficial effects of a national nicotine 
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reduction policy for reducing the burden of smoking and smoking-related consequences 





Table 1  













10-week outpatient study, 
within-in subjects design, 
participants smoked usual 
brand and cigarettes with 12, 
8, 4, 2 or 1 mg/g tobacco  
Withdrawal increased during 
the nicotine taper from baseline 
to Week 6 





11-day inpatient study, 
between-subjects design, 
random assignment to 
cigarettes with 0.6 or, 0.05 
mg of nicotine or a no 
smoking condition 
No significant differences in 









6-week outpatient study, 
between-subjects design, 
random assignment to 0.05 or 
0.3 mg yield cigarettes or 4 
mg nicotine lozenge 
The 0.05 mg cigarette was 
associated with reduced 
withdrawal whereas 0.3 mg was 
associated with increased 







6-week outpatient study, 
between-subjects design, 
random assignment to 0.05-
0.09 mg nicotine yield 
cigarettes, 21 mg patch or 
0.05-0.09 mg cigarettes with 
21 mg patch,  
all groups received 6 weeks 
of behavioral treatment  
Significant differences between 
groups with RNCCs+Patch 
group having lower withdrawal 
vs. Patch Alone  








subjects design, random 
assignment to usual brand 
cigarette or one of 6 types of 
research cigarettes ranging 
from 15.8 mg/g of tobacco to 
0.4 mg/g 
Cigarettes with 5.2 mg/g or less 
(vs. 15.8) did not significantly 
increase peak daily withdrawal 
during Weeks 1 or 6. Across the 
6 weeks, there were no 
significant differences in 
withdrawal by dose.  
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Table 2  
Baseline Demographic and Smoking Characteristics by Opioid-Maintenance Status 
 
Note. Mean + standard deviation unless otherwise noted; Bolded values represent p<.05; BDI, Beck 
Depression Inventory (Beck, 1996); OASIS, Overall Anxiety Severity and Impairment Scale (Norman et 










Maintained (NOM) p value 
N 200 65 135  
Demographics     
Age 35+12 41+11 32+10 <.001 
Female (%) 72 60 78 .01 
White (%) 76 72 77 .07 
Education (%)    .57 
  <High school 14 18 12  
  High school  
  degree/equivalent 35 35 34  
  Some college 40 37 41  
  Associate degree or higher 12 9 13  
Employment (%)    <.001 
  Full-time work 25 15 30  
  Part-time work 16 9 19  
  Casual employment 8 8 8  
  Unemployed 27 23 28  
  Other 25 45 16  
Marital Status (%)    <.01 
  Never married 61 52 65  
  Married 16 9 19  
  Divorced or separated 21 34 14  
  Widowed 3 5 1  
Smoking Characteristics     
Cigarettes/day 16+7 16+6 15+8 .06 
Intake CO level  22+11 23+12 21+11 .33 
Age started smoking regularly  16+4 16+5 16+3 .29 
FTCD total score 4.9+2 5.3+2 4.7+2 .03 
Menthol smoker (%) 35 35 34 .87 
Psychiatric Characteristics     
BDI total score 12+11 8+8 14+13 <.01 
OASIS total score 6+5 3+3 7+6 <.001 
Opioid Treatment Characteristics    
Methadone maintained (%)  58   
Methadone dose, mg   97+30   




Multivariable Models Predicting MTWS Total Scores at the Baseline Usual Brand 
Session (Session 1) and in Response to Cigarettes Varying in Nicotine Content  
(Sessions 2-5) 
 
Final models (All significant predictors)  Final models (All significant predictors with 
OM status forced in) 
Variable F value p value  Variable F value p value 
Session 1  Session 1 
Time 52.80 <.001  Time 52.80 <.001 
BDI 39.69 <.001  BDI 43.98 <.001 
FTCD 10.36 <.01  FTCD 9.01 <.01 
  OM Status 2.62 .11 
Sessions 2-5  Sessions 2-5 
Dose 3.65 .01  Dose 3.65 .02 
Time 97.30 <.001  Time 97.30 <.001 
Dose x Time 3.00 <.001  Dose x Time 3.00 <.01 
BDI 28.23 <.001  BDI 36.94 <.001 
Education 3.08 .03  Education 3.23 .03 
FTCD 9.34 <.01  FTCD 5.98 .02 
  Race 3.41 .04 
  OM Status 6.65 .01 
 
Table 4 
Multivariable Models Predicting MTWS Desire to Smoke at the Baseline Usual 
Brand Session (Session 1) and in Response to Cigarettes Varying in Nicotine 
Content (Sessions 2-5) 
 
Final models (All significant predictors)  Final models (All significant predictors with 
OM status forced in) 
Variable F value p value  Variable F value p value 
Session 1  Session 1 
Time 62.82 <.001  Time 62.82 <.001 
BDI 6.22 .01  BDI 6 .02 
FTCD 26.39 <.001  FTCD 25.54 <.001 
CO level 9.6 <.01  CO level 9.46 <.01 
    OM status 0.04 .84 
Sessions 2-5  Sessions 2-5 
Dose 8.77 <.001  Dose 8.77 <.001 
Time 130.93 <.001  Time 130.93 <.001 
Dose x Time 6.42 <.001  Dose x Time 6.42 <.001 
FTCD 32.09 <.001  FTCD 32.09 <.001 
OM status 0.88 .35  OM status 0.88 .35 
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Time x OM status 3.34 .01  Time x OM status 3.34 .01 
 
Table 5  
Multivariable Models Predicting MTWS Total and Desire to Smoke AUC Scores at 
the Baseline Usual Brand Session and in Response to Cigarettes Varying in 
Nicotine Content 
 MTWS Total Score AUC 
Final models (All significant predictors)  Final models (All significant predictors with 
OM status forced in) 
Variable F value p value  Variable F value p value 
Session 1  Session 1 
BDI 38.22 <.001  BDI 41.14 <.001 
FTCD 12.10 <.01  FTCD 10.26 <.01 
    OM status 2.61 .12 
Sessions 2-5  Sessions 2-5 
Dose 3.85 <.01  Dose 3.85 <.01 
BDI 36.70 <.001  BDI 36.70 <.001 
FTCD 6.71 .01  FTCD 6.71 .01 
Education 3.42 .02  Education 3.42 .02 
OM status 5.58 .02  OM status 5.58 .02 
 
 MTWS Desire to Smoke AUC 
Final models (All significant predictors)  Final models (All significant predictors with 
OM status forced in) 
Variable F value p value  Variable F value p value 
Session 1  Session 1 
BDI 5.78 .02  BDI 5.79 0.02 
FTCD 26.80 <.001  FTCD 25.74 <.001 
CO level 8.21 <.01  CO level 8.04 <.01 
    OM status 0.12 .73 
Sessions 2-5  Sessions 2-5 
Dose 10.55 <.001  Dose 10.55 <.001 
FTCD 34.83 <.001  FTCD 32.75 <.001 
    OM status 0.94 .33 
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Table 6  
Baseline Demographic and Smoking Characteristics of Phase 1 Completers vs. 
Noncompleters 
 All  Phase 1 Completer  Noncompleter  p value 
N 235 200 35  
Demographics     
Age 34 ± 12 35± 11 31 ± 12 .10 
Female (%)  73 72 77 .68 
White (%) 77 75 86 .23 
Education (%)    .27 
  <High school 13 14 6  
  High school  
  degree/equivalent  37 34 5  
  Some college 39 40 34  
  Associate degree or higher 11 11 9  
Employment (%)    .14 
  Full-time work 27 25 40  
  Part-time work 14 15 3  
  Casual employment 8 8 6  
  Unemployed 27 26 31  
  Other 24 25 20  
Marital Status (%)    .29 
  Never married 62 61 66  
  Married 14 16 6  
  Divorced or separated 22 20 29  
  Widowed 2 2 0  
Smoking Characteristics     
Cigarettes/day 16 ± 7 15 ± 7 18 ± 7 .05 
Intake CO level  22 ± 11 22 ± 11 21 ± 10 .81 
Age started smoking regularly  16 ± 4 16 ± 4 16 ± 3 .35 
FTCD total score 5 ± 2 5 ± 2 5 ± 2 .59 
Menthol smoker (%) 34 34 31 .85 
Note. Mean + standard deviation unless otherwise noted; Continuous variables were tested using the 







Figure 1. MTWS Total AUC scores from the parent study (Higgins et al., 2017), 
presented across nicotine doses by study sub-sample 














Withdrawal in Response to the Cigarettes Varying in Nicotine Content
MTWS Total Score





















General Study Inclusion 
Criteria:
• >18 years old
• Smoking > 5 cigarettes/day 
for past year
• Breath carbon monoxide > 8 
particles/million
2. Opioid-Maintained:
• 18-70 years old
• Receiving methadone or 
buprenorphine maintenance
• Stable on maintenance dose 
• No changes in dose in 
past 30 days
• <30% samples positive 




• Women   
• 18 – 44 years old
• < Associates degree
3. Affective Disorders:
• 18-70 years old
• Current DSM-IV diagnosis 





Figure 3. Overview of experimental procedures during baseline (Session 1) and Study 





• Arrive after 6-8 hours 
of abstinence (< 50% 
of intake CO)
• 2 puffs of usual brand 
cigarette to equate 
time since last 
smoked









• MTWS (Completed 






Figure 4. MTWS Total and Desire to Smoke scores at the baseline session across time by 
OM status 






































Figure 5. MTWS Total and Desire to Smoke AUC scores across nicotine dose by OM 
status 
Note. Error bars represent standard error of the mean. To ease interpretation of Aim 2 data involving 































MTWS Desire to Smoke
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